Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18253884rdf:typepubmed:Citationlld:pubmed
pubmed-article:18253884lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:18253884lifeskim:mentionsumls-concept:C0027686lld:lifeskim
pubmed-article:18253884lifeskim:mentionsumls-concept:C0431085lld:lifeskim
pubmed-article:18253884lifeskim:mentionsumls-concept:C0596290lld:lifeskim
pubmed-article:18253884lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:18253884lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:18253884lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:18253884lifeskim:mentionsumls-concept:C0053428lld:lifeskim
pubmed-article:18253884pubmed:issue1-2lld:pubmed
pubmed-article:18253884pubmed:dateCreated2008-2-6lld:pubmed
pubmed-article:18253884pubmed:abstractTextIn the present study, we investigated the potential anti-angiogenic mechanism and anti-tumour activity of beta-eudesmol using in vitro and in vivo experimental models. Proliferation of human umbilical vein endothelial cells (HUVEC) stimulated with vascular endothelial growth factor (VEGF, 30 ng/ml) and basic fibroblast growth factor (bFGF, 30 ng/ml) was significantly inhibited by beta-eudesmol (50-100 microM). Beta-eudesmol (100 microM) also blocked the phosphorylation of cAMP response element binding protein (CREB) induced by VEGF (30 ng/ml) in HUVEC. Beta-eudesmol (10-100 microM) inhibited proliferation of HeLa, SGC-7901, and BEL-7402 tumour cells in a time- and dose-dependent manner. Moreover, beta-eudesmol treatment (2.5-5 mg/kg) significantly inhibited growth of H(22) and S(180) mouse tumour in vivo. These results indicated that beta-eudesmol inhibited angiogenesis by suppressing CREB activation in growth factor signalling pathway. This is the first study to demonstrate that beta-eudesmol is an inhibitor of tumour growth.lld:pubmed
pubmed-article:18253884pubmed:languageenglld:pubmed
pubmed-article:18253884pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18253884pubmed:citationSubsetIMlld:pubmed
pubmed-article:18253884pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18253884pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18253884pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18253884pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18253884pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18253884pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18253884pubmed:statusMEDLINElld:pubmed
pubmed-article:18253884pubmed:issn1028-6020lld:pubmed
pubmed-article:18253884pubmed:authorpubmed-author:KimuraIkukoIlld:pubmed
pubmed-article:18253884pubmed:authorpubmed-author:WangMin-WeiMWlld:pubmed
pubmed-article:18253884pubmed:authorpubmed-author:TsunekiHirosh...lld:pubmed
pubmed-article:18253884pubmed:authorpubmed-author:XiaoJin-FangJ...lld:pubmed
pubmed-article:18253884pubmed:authorpubmed-author:XiaMing-YuMYlld:pubmed
pubmed-article:18253884pubmed:authorpubmed-author:LiYan-ChunYClld:pubmed
pubmed-article:18253884pubmed:authorpubmed-author:MaEn-LongELlld:pubmed
pubmed-article:18253884pubmed:issnTypePrintlld:pubmed
pubmed-article:18253884pubmed:volume10lld:pubmed
pubmed-article:18253884pubmed:ownerNLMlld:pubmed
pubmed-article:18253884pubmed:authorsCompleteYlld:pubmed
pubmed-article:18253884pubmed:pagination159-67lld:pubmed
pubmed-article:18253884pubmed:dateRevised2009-7-21lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:meshHeadingpubmed-meshheading:18253884...lld:pubmed
pubmed-article:18253884pubmed:articleTitleBeta-eudesmol suppresses tumour growth through inhibition of tumour neovascularisation and tumour cell proliferation.lld:pubmed
pubmed-article:18253884pubmed:affiliationDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China. maenlong@hotmail.comlld:pubmed
pubmed-article:18253884pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18253884pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed